TY - JOUR T1 - Dr. Khan, Dr. Hanley, and Dr. Peters reply JF - The Journal of Rheumatology JO - J Rheumatol SP - 453 LP - 453 DO - 10.3899/jrheum.080808 VL - 36 IS - 2 AU - ALIYA KHAN AU - DAVID A. HANLEY AU - EDMUND PETERS Y1 - 2009/02/01 UR - http://www.jrheum.org/content/36/2/453.1.abstract N2 - We thank Dr. Fung and Dr. Campisi and colleagues for their responses. The points raised by Dr. Fung are of value and have been emphasized in the editorial recently published in The Journal1. His other comments pertaining to the need to adjudicate reported cases have also been stressed in our systematic review on bisphosphonate (BP) associated osteonecrosis of the jaw (ONJ)2. The systematic review provides the incidence data in patient-years to ensure that these data are not misinterpreted. BP are of great benefit in the management of osteoporosis and other metabolic bone disorders, and if utilized appropriately according to the recently published guidelines3 are safe and effective agents. Data in the Canadian survey will shed more light on this issue, as pointed out by Dr. Fung, and are eagerly awaited. In response to the issues presented by … Address reprint requests to Dr. Khan; E-mail: avkhan{at}aol.com ER -